Review
Medicine, General & Internal
Carla R. Copeland, Lisa H. Lancaster
Summary: Progressive fibrosing interstitial lung diseases (PF-ILD) is a diverse group of interstitial lung diseases characterized by accelerated respiratory failure, frequent disease exacerbation, and earlier mortality. Available therapeutic approaches include antifibrotic therapy, immunosuppression, novel therapies, and lung transplantation.
FRONTIERS IN MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Xie Xiaohong, Wang Liqiang, Li Na, Lin Xinqing, Qin Yinyin, Liu Ming, Ouyang Ming, Han Qian, Luo Qun, Li Shiyue, Li Chunyan, Wang Xiaoqian, Yang Shuanying, Huang Wei, Liu Mei, Wang Ping, Zhou Chengzhi
Summary: This study investigated the management and prognosis of ILD-LC patients in China, revealing that patients have poor survival rates and appropriate anti-tumor treatments can prolong survival. Surgery is preferred for early-stage lung cancer patients, while anti-angiogenic regimens significantly improve the prognosis for advanced-stage ILD-LC patients.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Respiratory System
Avignat S. S. Patel, Ezra Miller, Shawn M. M. Regis, Gary M. M. Hunninghake, Lori Lyn Price, Melissa Gawlik, Andrea B. B. McKee, Kimberly M. M. Rieger-Christ, Victor Pinto-Plata, Timothy N. N. Liesching, Christoph Wald, Jeffrey Hashim, Brady J. J. McKee, Lee Gazourian
Summary: This study aimed to determine the prevalence of interstitial lung abnormalities (ILA) in a large CT lung cancer screening program and explore their association with clinically significant outcomes. The results showed that individuals with ILA had a higher risk of mortality and ILD diagnosis compared to those without ILA, but there was no significant difference in lung cancer and hospitalization.
RESPIRATORY RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Wei Wu, Bridget F. F. Collins, Gregory C. C. Gardner, Daniel S. S. Hippe, Lawrence A. A. Ho, Ganesh Raghu, Sudhakar N. J. Pipavath
Summary: This study analyzed the CT patterns of 47 patients with antisynthetase syndrome-related interstitial lung disease (ASyS-ILD) and its impact on survival. The study found that 56.7% of patients presented with non-fibrotic patterns on CT, with 23.3% showing improvement and 82.4% exhibiting fibrotic patterns, among which 17.6% had progression. Age and CT progression were associated with reduced survival, while the presence of ground-glass opacities and predominant lower lobe distribution were associated with increased survival.
EUROPEAN RADIOLOGY
(2023)
Review
Respiratory System
Aislin Fields, Koray N. Potel, Rhandel Cabuhal, Buena Aziri, Iain D. Stewart, Bettina C. Schock
Summary: This study systematically reviews the potential of soluble markers in peripheral blood or bronchoalveolar lavage fluid (BALF) as biomarkers in the diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). The results suggest that IL-8, SP-D, and KL-6 have the potential to serve as reliable biomarkers in blood/BALF for supporting the diagnosis of SSc-ILD. However, further investigation is needed to determine the independent value of other biomarkers in diagnosis and prognosis.
Article
Medicine, General & Internal
Xiaoyi Feng, Yishan Duan, Xiafei Lv, Qinxue Li, Binmiao Liang, Xuemei Ou
Summary: The presence of lung cancer does not significantly increase the risk of acute exacerbation (AE) as a natural course of combined pulmonary fibrosis and emphysema (CPFE). However, CPFE patients with lung cancer tend to be elderly male smokers and have higher levels of inflammatory markers. Pack-years, family history of cancer, fibrinogen levels, and serum C3 levels are independently associated with the presence of lung cancer in CPFE patients. Clinicians should closely monitor CPFE patients, especially those with severe fibrosis and systemic inflammation, for the development of AE.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
John N. Shumar, Abhimanyu Chandel, Christopher S. King
Summary: Progressive fibrosing interstitial lung disease (PF-ILD) is a subset of interstitial lung diseases characterized by progressive and intractable lung fibrosis, with similarities to idiopathic pulmonary fibrosis. Recent studies have shown the clinical efficacy of antifibrotic therapy in PF-ILD, changing the treatment landscape for fibrotic lung diseases and opening the door for combined therapies targeting both fibrotic and inflammatory components.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Elisabetta Zanatta, Andrea Martini, Roberto Depascale, Anna Gamba, Marta Tonello, Mariele Gatto, Chiara Giraudo, Elisabetta Balestro, Andrea Doria, Luca Iaccarino
Summary: By assessing the role of CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-ILD) in idiopathic inflammatory myopathies (IIMs), we found that CCL18 may be a useful biomarker in IIMs-ILD, particularly in the early identification of patients at risk of developing PF-ILD.
Article
Respiratory System
Julien Guiot, Monique Henket, Anne-Noelle Frix, Fanny Gester, Marie Thys, Laurie Giltay, Colin Desir, Catherine Moermans, Makon-Sebastien Njock, Paul Meunier, Jean-Louis Corhay, Renaud Louis
Summary: This study describes the phenotype and functional characteristics of patients with combined obstructive and interstitial lung disease, and identifies specific functional patterns and risk factors for poor prognosis in these patients. Further research is needed to understand treatment response in this population, as they are typically excluded from clinical trials.
RESPIRATORY RESEARCH
(2022)
Article
Oncology
Jae Myoung Noh, Hongseok Yoo, Woojin Lee, Hye Yun Park, Sun Hye Shin, Hongryull Pyo
Summary: Underlying lung disease can affect the pulmonary toxicity after radiotherapy for lung cancer. Idiopathic pulmonary fibrosis is associated with severe pulmonary toxicity and poor survival even after proton beam therapy (PBT), while PBT seems to be a safe treatment modality for lung cancer patients with chronic obstructive pulmonary disease.
Review
Medicine, Research & Experimental
Antonio Poerio
Summary: Interstitial lung disease (ILD) is a common manifestation of connective tissue diseases (CTDs), especially in patients with rheumatoid arthritis (RA) and systemic sclerosis (SSc). Recent interest has focused on pulmonary manifestations of ILD-CTDs due to the increased use of anti-fibrotic drugs. Radiologists play a crucial role in assessing ILD-CTDs using imaging techniques, as lung biopsies are rarely performed in these patients.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Medicine, General & Internal
Dieter Munker, Paola Arnold, Gabriela Leuschner, Michael Irlbeck, Sebastian Michel, Teresa Kauke, Bruno Meiser, Juergen Behr, Nikolaus Kneidinger, Tobias Veit
Summary: This retrospective study evaluated the potential effects of immunosuppressants and antifibrotics on the perioperative course of patients with interstitial lung diseases undergoing lung transplantation. The results showed that pretreatment with antifibrotics could shorten the duration of mechanical ventilation and reduce the occurrence of de novo donor-specific antibodies. Therefore, the use of antifibrotics alone or in combination with immunosuppressive therapy in lung transplant patients with fibrotic lung diseases is safe and may have beneficial effects.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Nicol Bernardinello, Elisabetta Cocconcelli, Annalisa Boscolo, Gioele Castelli, Nicolo Sella, Chiara Giraudo, Elisabetta Zanatta, Federico Rea, Marina Saetta, Paolo Navalesi, Paolo Spagnolo, Elisabetta Balestro
Summary: Diaphragm ultrasound can be used to assess diaphragm function in patients with ILD. The prevalence of diaphragmatic dysfunction was 29% in patients with ILD and it was associated with dyspnea. CTD-ILD had lower diaphragm displacement compared to IPF and a higher prevalence of diaphragmatic dysfunction compared to controls.
RESPIRATORY MEDICINE
(2023)
Review
Oncology
Katarzyna Dziadziuszko, Edyta Szurowska
Summary: The final results of the two largest randomized lung cancer screening trials in the United States and Europe confirmed the reduction in mortality rate with low-dose computed tomography screening. This led to widespread acceptance of LCS in high-risk populations and highlighted the importance of clear screening protocols and the application of risk prediction models for improved accuracy.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Respiratory System
Yunjoo Im, Man Pyo Chung, Kyung Soo Lee, Joungho Han, Myung Jin Chung, Hong Kwan Kim, Jong Ho Cho, Yong Soo Choi, Sujin Park, Ho Joong Kim, O. Jung Kwon, Boram Park, Hongseok Yoo
Summary: Interstitial lung abnormalities (ILAs) are associated with increased treatment-related complications and decreased survival in patients who underwent curative surgery for lung cancer.
Review
Oncology
Jacques-Olivier Bay, Carole Bouleuc, Nelly Firmin, Virginie Gandemer, Nicolas Magne, Daniel Orbach, Nicolas Penel, Manuel Rodrigues, Antoine Thiery-Vuillemin, Marie Wislez, Gilles L'Allemain, Renaud Sabatier, Jacques Robert
Summary: This article presents a summary of the most important advances in treatment and patient care in oncology in 2021, including breast and gynecological cancers (endometrium and cervix), lung cancer, brain cancer, urologic cancer, and digestive cancers. It also highlights progresses in hematological malignancies, pediatric oncology, and supportive care for patients.
BULLETIN DU CANCER
(2022)
Review
Oncology
Laurent Greillier, Manon Gauvrit, Elena Paillaud, Nicolas Girard, Coline Montegut, Rabia Boulahssass, Marie Wislez, Frederic Pamoukdjian, Romain Corre, Mathilde Cabart, Philippe Caillet, Yaniss Belaroussi, Matthieu Frasca, Pernelle Noize, Pascal Wang, Soraya Mebarki, Simone Mathoulin-Pelissier, Anne-Laure Couderc
Summary: This study conducted a systematic review of the efficacy, toxicity, and feasibility of targeted therapy in older patients with non-small cell lung cancer (NSCLC). Guidelines were developed based on the findings to help clinicians adapt the type of targeted therapy based on the oncological and geriatric profile of older NSCLC patients. The expert panel concluded that osimertinib is recommended as a first-line treatment for older patients with EGFR mutation. However, there is limited data and no definitive recommendations for older patients with ALK and ROS1 rearrangements. Assessment of malnutrition, functional decline, and comorbidities is important before initiating targeted therapy.
Article
Oncology
J. Tredaniel, F. Barlesi, C. Le Pechoux, D. Lerouge, E. Pichon, S. Le Moulec, L. Moreau, S. Friard, V. Westeel, L. Petit, O. Carre, F. Guichard, O. Raffy, J. Villa, A. Prevost, A. Langlais, F. Morin, M. Wislez, P. Giraud, G. Zalcman, F. Mornex, for the French Cooperative Thoracic Intergroup (IFCT) French Cooperat Thoracic Intergrp IFCT
Summary: The IFCT-0803 trial evaluated the addition of cetuximab to cisplatin and pemetrexed chemoradiotherapy in patients with non-small-cell lung cancer, showing excellent disease control rate and survival rates.
CANCER RADIOTHERAPIE
(2022)
Article
Oncology
Helene Goussault, Sebastien Gendarme, Jean-Baptiste Assie, Camille Jung, Salome Epaud, Christelle Algans, Noemie Salaun-Penquer, Mathilde Rousseau, Andrea Lazatti, Christos Chouaid
Summary: Despite therapeutic advances, lung cancer remains the leading cause of cancer-related death. This study aimed to identify the risk factors associated with death within 3 months of the first hospitalization for lung cancer in France. The results showed that early mortality was influenced by age, gender, disease metastasis at diagnosis, hospitalization via the emergency room, and duration of hospitalization. Socioeconomic characteristics, on the other hand, were not associated with early mortality. Improving survival rates for lung cancer patients requires early diagnosis and better organization of diagnosis and specific care pathways.
Article
Economics
Valentine Grumberg, Christos Chouaid, Francois-Emery Cotte, Baptiste Jouaneton, Ronan Jolivel, Anne-Francoise Gaudin, Dorothee Reynaud, Jean-Baptiste Assie, Isabelle Borget
Summary: Healthcare resource utilization and costs for patients with advanced non-small cell lung cancer (aNSCLC) treated with nivolumab decreased over time.
JOURNAL OF MEDICAL ECONOMICS
(2022)
Article
Oncology
Renaud Descourt, Maurice Perol, Gaelle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Jacques Cadranel, Alexis Benjamin Cortot, Florian Guisier, Loick Galland, Pascal Do, Roland Schott, Eric Dansin, Jennifer Arrondeau, Jean-Bernard Auliac, Margaux Geier, Christos Chouaid
Summary: This analysis evaluates the efficacy of brigatinib in ALK(+) advanced non-small cell lung cancer patients, with a focus on post-brigatinib lorlatinib efficacy. The results show that brigatinib is effective in heavily pretreated patients and lorlatinib demonstrates activity after brigatinib.
Article
Oncology
Jean-Baptiste Assie, Florian Crepin, Emmanuel Grolleau, Anthony Canellas, Margaux Geier, Aude Grebert-Manuardi, Nabila Akkache, Aldo Renault, Pierre-Alexandre Hauss, Marielle Sabatini, Valentine Bonnefoy, Alexis Cortot, Marie Wislez, Clement Gauvain, Christos Chouaid, Arnaud Scherpereel, Isabelle Monnet
Summary: This study evaluated the real-life efficacy of second-line and onward nivolumab in malignant pleural mesothelioma patients in France and identified predictive factors for treatment response.
Article
Oncology
Sebastien Gendarme, Jean-Claude Pairon, Pascal Andujar, Francois Laurent, Patrick Brochard, Fleur Delva, Benedicte Clin, Antoine Gislard, Christophe Paris, Isabelle Thaon, Helene Goussault, Florence Canoui-Poitrine, Christos Chouaid
Summary: This study analyzed the cost-effectiveness ratio of implementing a lung cancer screening program for asbestos-exposed population. The results show that biennial screening for smokers with high asbestos exposure is cost-effective.
Correction
Oncology
Maxime Boussageon, Aurelie Swalduz, Christos Chouaid, Olivier Bylicki
Article
Oncology
Jacques-Olivier Bay, Carole Bouleuc, Christophe Caux, Frederic Delom, Nelly Firmin, Virginie Gandemer, Gilles L'Allemain, Nicolas Magne, Daniel Orbach, Jacques Robert, Manuel Rodrigues, Renaud Sabatier, Antoine Thiery-Vuillemin, Marie Wislez
Summary: This article presents the analysis of highlights from 2022 by the editorial committee members of The Cancer Bulletin. Their objective is to provide readers with a thoughtful, educational, and practical reading by analyzing published data and placing it in the context of cancer management. The goal is to offer rational bases for different treatment approaches in 2023.
BULLETIN DU CANCER
(2023)
Article
Oncology
Pascal Wang, Jeanne Chapron, Souhail Bennani, Marie-Pierre Revel, Marie Wislez
Summary: Lung cancer is the main cause of cancer deaths in France and worldwide, with an overrepresentation of metastatic stages at diagnosis. Multiple randomized trials have evaluated the use of low-dose chest CT for early detection and have shown a reduction in lung cancer-specific mortality. The challenge now is to implement a national CT screening policy that is effective, cost-efficient, and minimizes harm to eligible individuals.
BULLETIN DU CANCER
(2023)
Article
Oncology
Arnaud Scherpereel, Etienne Martin, Laurent Brouchet, Romain Corre, Michael Duruisseaux, Pierre-Emmanuel Falcoz, Philippe Giraud, Cecile Le Pechoux, Marie Wislez, Marco Alifano
Summary: This modified Delphi study aimed to generate agreement through multidisciplinary decision-making on the clinical management of non-bulky/non-infiltrative stage IIIA N2 NSCLC. The study found that there was agreement on endo-bronchial ultrasound/endoscopic ultrasound as the preferred method for initial mediastinal staging and on the use of surgery and (neo)adjuvant chemotherapy as first-line treatment for single-station disease. It also showed consensus on the use of concurrent chemo-radiotherapy with adjuvant immunotherapy for patients with multi-station N2 disease.
Article
Oncology
Remy Ezzedine, Anthony Canellas, Charles Naltet, Marie Wislez, Reza Azarian, Andrei Seferian, Etienne Giroux Leprieur
Summary: Chemoimmunotherapy has shown superiority in the real-life treatment of advanced small cell lung cancer, especially in patients with brain and liver metastases. However, it is not beneficial for patients aged 70 or older with impaired performance status.
Article
Oncology
Jean-Baptiste Assie, Christos Chouaid, Hilario Nunes, Dorothee Reynaud, Anne-Francoise Gaudin, Valentine Grumberg, Ronan Jolivel, Baptiste Jouaneton, Francois-Emery Cotte, Boris Duchemann
Summary: This study evaluated the survival outcome following nivolumab treatment in non-small cell lung cancer (NSCLC) patients with pre-treated interstitial lung disease (ILD) in a real-world setting. The results showed that the outcomes of ILD patients treated with nivolumab were similar to those of non-ILD patients, suggesting that immunotherapy could be beneficial for these patients.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
